Efficacy of individualised diets in patients with irritable bowel syndrome: A randomised controlled trial

BMJ Open Gastroenterology

Volumn 4, Issue 1, 2017, Pages

  Ali, Ather ^a   Weiss, Theresa R ^a   McKee, Douglas ^b   Scherban, Alisa ^a   Khan, Sumiya ^a   Fields, Maxine R ^a   Apollo, Damian ^a   Mehal, Wajahat Z ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Department of Obstetrics Gynecology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; APTAMER; DISACCHARIDE; LEUKOCYTE ELASTASE; LOPERAMIDE; MONOSACCHARIDE; OLIGOSACCHARIDE; POLYOL; SPASMOLYTIC AGENT;

ADULT; ARTICLE; ASSESSMENT OF HUMANS; BLOOD EXAMINATION; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIET THERAPY; DIETARY COMPLIANCE; DIETARY FIBER; DOUBLE BLIND PROCEDURE; FAINTNESS; FEMALE; FOOD INTAKE; HEALTH CENTER; HUMAN; IBS ADEQUATE RELIEF; IBS GLOBAL IMPROVEMENT SCALE; IBS SYMPTOM SEVERITY SCALE; INTENTION TO TREAT ANALYSIS; IRRITABLE COLON; LEUKOCYTE ACTIVATION; LEUKOCYTE ACTIVATION TEST; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PARALLEL DESIGN; PERSONALIZED MEDICINE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEOMICS; QUALITY OF LIFE; QUALITY OF LIFE INDEX; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RISK REDUCTION; THERAPY EFFECT; TREATMENT DURATION; UNITED STATES; VENOUS BLOOD; YOUNG ADULT;

EID: 85045189803     PISSN: None     EISSN: 20544774     Source Type: Journal    
DOI: 10.1136/bmjgast-2017-000164     Document Type: Article

References (54)

1. Hungin AP, Chang L, Locke GR, et al. Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact. Aliment Pharmacol Ther 2005;21:1365-75.
2. Gaman A, Bucur MC, Kuo B. Therapeutic advances in functional gastrointestinal disease: irritable bowel syndrome. Therap Adv Gastroenterol 2009;2:169-81.
3. Simrén M, Månsson A, Langkilde AM, et al. Food-related gastrointestinal symptoms in the irritable bowel syndrome. Digestion 2001;63:108-15.
4. Magge S, Lembo A. Low-FODMAP Diet for Treatment of Irritable Bowel Syndrome. Gastroenterol Hepatol 2012;8:739-45.
5. Gibson PR, Varney J, Malakar S, et al. Food components and irritable bowel syndrome. Gastroenterology 2015;148:1158-74.
6. Farah DA, Calder I, Benson L, et al. Specific food intolerance: its place as a cause of gastrointestinal symptoms. Gut 1985;26:164-8.
7. Chey WD. Food: The Main Course to Wellness and Illness in Patients With Irritable Bowel Syndrome. Am J Gastroenterol 2016;111:366-71.
8. Enck P, Aziz Q, Barbara G, et al. Irritable bowel syndrome. Nat Rev Dis Primers 2016;2:16014.
9. Bernstein M, Day JH, Welsh A. Double-blind food challenge in the diagnosis of food sensitivity in the adult. J Allergy Clin Immunol 1982;70:205-10.
10. Bengtsson U, Nilsson-Balknäs U, Hanson LA, et al. Double blind, placebo controlled food reactions do not correlate to IgE allergy in the diagnosis of staple food related gastrointestinal symptoms. Gut 1996;39:130-5.
11. Atkinson W, Sheldon TA, Shaath N, et al. Food elimination based on IgG antibodies in irritable bowel syndrome: A randomised controlled trial. Gut 2004;53:1459-64.
12. Teuber SS, Beyer K. IgG to foods: A test not ready for prime time. Curr Opin Allergy Clin Immunol 2007;7:257-8.
13. Ali A, Scoulios N, Ten N, et al. A National Assessment of the Usage, Cost, and Reimbursement of Unconventional Medical Laboratory Tests. The Journal of Alternative and Complementary Medicine 2014;20:A3-A4.
14. Wüthrich B. Unproven techniques in allergy diagnosis. J Investig Allergol Clin Immunol 2005;15:86-90.
15. Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology 2006;130:1480-91.
16. Lembo T, Wright RA, Bagby B, et al. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2001;96:2662-70.
17. Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: A simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther 1997;11:395-402.
18. Bijkerk CJ, de Wit NJ, Muris JW, et al. Outcome measures in irritable bowel syndrome: comparison of psychometric and methodological characteristics. Am J Gastroenterol 2003;98:122-7.
19. Kaptchuk TJ, Friedlander E, Kelley JM, et al. Placebos without deception: A randomized controlled trial in irritable bowel syndrome. PLoS One 2010;5:e15591.
20. Johannesson E, Ringström G, Abrahamsson H, et al. Intervention to increase physical activity in irritable bowel syndrome shows longterm positive effects. World J Gastroenterol 2015;21:600-8.
21. Lembo AJ, Conboy L, Kelley JM, et al. A treatment trial of acupuncture in IBS patients. Am J Gastroenterol 2009;104:1489-97.
22. Pedersen N, Andersen NN, Végh Z, et al. Ehealth: low FODMAP diet vs Lactobacillus rhamnosus GG in irritable bowel syndrome. World J Gastroenterol 2014;20:16215-26.
23. Wang XX, Luo RJ, She B, et al. Traditional Chinese medicine (Shun- Qi-Tong-Xie Granule) for irritable bowel syndrome: study protocol for a randomised controlled trial. Trials 2014;15:273.
24. Passos MC, Lembo AJ, Conboy LA, et al. Adequate relief in a treatment trial with IBS patients: A prospective assessment. Am J Gastroenterol 2009;104:912-9.
25. Drossman DA, Patrick DL, Whitehead WE, et al. Further validation of the IBS-QOL: A disease-specific quality-of-life questionnaire. Am J Gastroenterol 2000;95:999-1007.
26. Finniss DG, Kaptchuk TJ, Miller F, et al. Biological, clinical, and ethical advances of placebo effects. Lancet 2010;375:686-95.
27. Benedetti F. Placebo and the new physiology of the doctor-patient relationship. Physiol Rev 2013;93:1207-46.
28. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society Series B 1995;57:289-300.
29. Yao CK, Gibson PR, Shepherd SJ. Design of clinical trials evaluating dietary interventions in patients with functional gastrointestinal disorders. Am J Gastroenterol 2013;108:748-58.
30. Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale, N.J.: L. Erlbaum Associates, 1988.
31. Levine RJ. Ethics and Regulation of Clinical Research. 2nd ed. New Haven: Yale University Press, 1986.
32. Katz DL, Jekel JF. Jekel's epidemiology, biostatistics, preventive medicine, and public health. 4th ed. Philadelphia; London: Saunders, 2014.
33. Delgado-Rodriguez M, Bias LJ. J Epidemiol Community Health 2004;58:635-41.
34. Peduzzi P, Henderson W, Hartigan P, et al. Analysis of randomized controlled trials. Epidemiol Rev 2002;24:26-38.
35. Elsenbruch S, Enck P. Placebo effects and their determinants in gastrointestinal disorders. Nat Rev Gastroenterol Hepatol 2015;12:472-85.
36. Lexchin J, Bero LA, Djulbegovic B, et al. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003;326:1167-70.
37. Rodwin MA, Abramson JD. Clinical trial data as a public good. JAMA 2012;308:871-2.
38. Courneya KS. Efficacy, effectiveness, and behavior change trials in exercise research. Int J Behav Nutr Phys Act 2010;7:81.
39. Mayer EA, Tillisch K, Gupta A. Gut/brain axis and the microbiota. J Clin Invest 2015;125:926-38.
40. Buckley MM, O'Mahony SM, O'Malley D. Convergence of neuroendocrine- immune pathways in the pathophysiology of irritable bowel syndrome. World J Gastroenterol 2014;20:8846-58.
41. Steffen R, Hill DR, DuPont HL. Traveler's diarrhea: A clinical review. JAMA 2015;313:71-80.
42. Jüni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ 2001;323:42-6.
43. Gibson PR. Food intolerance in functional bowel disorders. J Gastroenterol Hepatol 2011;26 Suppl 3(Suppl 3):128-31.
44. Eswaran SL, Chey WD, Jackson K, et al. 821 A Low FODMAP Diet Improves Quality of Life, Reduces Activity Impairment, and Improves Sleep Quality in Patients With Irritable Bowel Syndrome and Diarrhea: Results From a U.S. Randomized, Controlled Trial. Gastroenterology 2016;150:S172.
45. Böhn L, Störsrud S, Liljebo T, et al. Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: A randomized controlled trial. Gastroenterology 2015;149:1399-407.
46. Monash University. The Monash University Low FODMAP Diet, 2016. (Version 2.0.1) (Mobile application software). http://itunes.apple.com/.
47. Bischoff SC, Barbara G, Buurman W, et al. Intestinal permeability-A new target for disease prevention and therapy. BMC Gastroenterol 2014;14:189.
48. Lollo B, Steele F, Gold L. Beyond antibodies: new affinity reagents to unlock the proteome. Proteomics 2014;14:638-44.
49. Barbara G, Stanghellini V, De Giorgio R, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004;126:693-702.
50. Park CH, Joo YE, Choi SK, et al. Activated mast cells infiltrate in close proximity to enteric nerves in diarrhea-predominant irritable bowel syndrome. J Korean Med Sci 2003;18:204-10.
51. Ginzberg HH, Cherapanov V, Dong Q, et al. Neutrophil-mediated epithelial injury during transmigration: Role of elastase. Am J Physiol Gastrointest Liver Physiol 2001;281:G705-17.
52. Garcia-Martinez I, Weiss T, Ali A, et al. The Alcat Test Predicts the Release of DNA and Myeloperoxidase by Innate Immune Peripheral Blood Leukocytes via a PKC Dependent Pathway. J Altern Complement Med 2016:A23.
53. Ford AC, Moayyedi P. Meta-Analysis: factors affecting placebo response rate in the irritable bowel syndrome. Aliment Pharmacol Ther 2010;32:144-58.
54. Patel SM, Stason WB, Legedza A, et al. The placebo effect in irritable bowel syndrome trials: A meta-Analysis. Neurogastroenterol Motil 2005;17:332-40.